Plant-Derived Vaccines: A Sustainable Approach to Disease Control for Global Health

Year : 2025 | Volume : 15 | Issue : 01 | Page : 17 20
    By

    D.V Surya Prakash,

  • Kirti Mittal,

  • Tooba Rizvi,

  • Sachin Kumar Tomar,

  • Gourav Mishra,

  1. Assistant Professor, Department of Biotechnology, Meerut Institute of Engineering and Technology, Meerut, Uttar Pradesh, India
  2. B.Tech. Student, Department of Biotechnology, Meerut Institute of Engineering and Technology, Meerut, Uttar Pradesh, India
  3. B.Tech. Student, Department of Biotechnology, Meerut Institute of Engineering and Technology, Meerut, Uttar Pradesh, India
  4. Assistant Professor, Department of Biotechnology, Meerut Institute of Engineering and Technology, Meerut, Uttar Pradesh, India
  5. Assistant Professor, Department of Biotechnology, Meerut Institute of Engineering and Technology, Meerut, Uttar Pradesh, India

Abstract

Plant-based vaccines present a novel and environmentally responsible approach to vaccination, with significant potential for improving both human and animal health. These vaccines are safer and less expensive than traditional vaccine manufacturing methods because they use genetically modified plants to create antigens that elicit an immune response. Plant-based systems offer a potential remedy for traditional vaccines’ high production costs and environmental impact, which are growing problems. Plant-derived vaccines have shown potential in treating bacterial and viral infections in people, and they provide a means of reducing zoonotic diseases and improving animal health in veterinary medicine. This method is especially well-suited for application in regions with limited resources since it offers advantages in terms of scalability, ease of storage, and a decreased dependency on cold-chain logistics. Regulatory obstacles, immunogenicity issues, and the difficulties of large-scale manufacturing are still obstacles, nevertheless. This study highlights the revolutionary potential of plant-based vaccines in global healthcare by examining their developments, challenges, and potential future applications in both human and animal health.

Keywords: Plant, Vaccine, Health, Diseases, Technology

[This article belongs to Research and Reviews: A Journal of Microbiology and Virology ]

How to cite this article:
D.V Surya Prakash, Kirti Mittal, Tooba Rizvi, Sachin Kumar Tomar, Gourav Mishra. Plant-Derived Vaccines: A Sustainable Approach to Disease Control for Global Health. Research and Reviews: A Journal of Microbiology and Virology. 2025; 15(01):17-20.
How to cite this URL:
D.V Surya Prakash, Kirti Mittal, Tooba Rizvi, Sachin Kumar Tomar, Gourav Mishra. Plant-Derived Vaccines: A Sustainable Approach to Disease Control for Global Health. Research and Reviews: A Journal of Microbiology and Virology. 2025; 15(01):17-20. Available from: https://journals.stmjournals.com/rrjomv/article=2025/view=193220


References

  1. Aggarwal S. (2009). What’s fueling the biotech engine-2008. Nat. Biotechnol, 27, 987–993.
  2. Antoniou E., Orovou E., Sarella A., Iliadou M., Rigas N., Palaska E., et al. (2020). Zika virus and the risk of developing microcephaly in infants: A systematic review. Int. J. Environ. Res. Public Health, 17, 3806.
  3. Ashraf S., Singh P. K., Yadav D. K., Shahnawaz M., Mishra S., Sawant S. V., et al. (2005). High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice. J. Biotechnol, 119, 1–14.
  4. Armbruster N., Jasny E., Petsch B. (2019). Advances in RNA vaccines for preventive indications: a case study of a vaccine against rabies. Vaccines, 7, 132.
  5. Avesani L., Merlin M., Gecchele E., Capaldi S., Pezzotti M. (2013). Comparative analysis of different biofactories for the production of a major diabetes autoantigen. Transgenic Res, 23, 281–291.
  6. Bailey J. R., Barnes E., Cox A. L. (2019). Approaches, progress, and challenges to hepatitis c vaccine development. Gastroenterology, 156, 418–430.
  7. Bock R. (2015). Engineering plastid genomes: methods, tools, and applications in basic research and biotechnology. Annu. Rev. Plant Biol. 66, 211–241.
  8. Bock R., Warzecha H. (2010). Solar-powered factories for new vaccines and antibiotics. Trends Biotechnol, 28, 246–252.
  9. Gillard P., Yang P. C., Danilovits M., Su W. J., Cheng S. L., Pehme L., et al. (2016). Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study. Tuberculosis,100 118–127.
  10. Castells-Graells R., Lomonossoff G. P. (2021). Plant-based production can result in covalent cross-linking of proteins. Plant Biotechnol. J., 19, 1095–1097.
  11. Chen Y., Guo D. (2016). Molecular mechanisms of coronavirus RNA capping and methylation. Virol. Sin., 31, 3–11.
  12. Chen H. Y., Zhang J., Gao Y., Du H. L., Ma Y., Zheng W. Z., et al. (2002). Transforming HBsAg into peanut and detection of its immunogenecity. Lett. Biotechnol., 4, 245–250.
  13. De Araújo T. V. B., Rodrigues L. C., De Alencar Ximenes R. A., De Barros Miranda-Filho D., Montarroyos U. R., de Melo A. P. L., et al. (2016). Association between zika virus infection and microcephaly in Brazil, January to May 2016: Preliminary report of a case-control study. Lancet Infect. Dis., 16, 1356–1363.
  14. Dobrica M. O., Lazar C., Paruch L., Skomedal H., Steen H., Haugslien S., et al. (2017). A novel chimeric hepatitis b virus S/preS1 antigen produced in mammalian and plant cells elicits stronger humoral and cellular immune response than the standard vaccine-constituent. s protein. Antivir. Res., 144, 256–265.
  15. Farsad A. S., Malek Zadeh S., Moshtaqi N., Fotouhi F., Zibaei S. (2016). Transient expression of HA1 antigen of avian influenza virus (H5N1) in alfalfa, soybean and lettuce leaves by agroinfiltration. Agric. Biotechnol. J., 8, 61–80.
  16. Ellis R. D., Hatherill M., Tait D., Snowden M., Churchyard G., Hanekom W., et al. (2015). Innovative clinical trial designs to rationalize TB vaccine development. Tuberculosis, 95, 352–357.
  17. Matz, K. M., Marzi, A., Feldmann, H (2019). Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Rev. Vaccines, 18, 1229–1242.
  18. Jindani A., Harrison T. S., Nunn A. J., Phillips P. P., Churchyard G. J., Charalambous S., et al. (2014). High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. New Eng. J. Med.,371 1599–1608.
Regular Issue Subscription Review Article
Volume 15
Issue 01
Received 13/12/2024
Accepted 26/12/2024
Published 09/01/2025
Publication Time 27 Days
342

Login


My IP

PlumX Metrics